Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis

被引:17
|
作者
Shi, J [1 ]
Kovacs, SJ
Wang, YN
Ludden, TM
Bhargava, VO
机构
[1] Aventis Pharmaceut, Global Biopharmaceut Drug Metab & Pharmacokinet, Bridgewater, NJ 08807 USA
[2] Aventis Pharmaceut, US Med Res, Clin Pharmacol, Bridgewater, NJ USA
[3] GloboMax, Pharmacometr Res & Dev, Hanover, MD USA
[4] Forest Labs Inc, Clin Pharmacol & Drug Dynam, Jersey City, NJ USA
关键词
leflunomide; population pharmacokinetics; juvenile rheumatoid arthritis; pediatrics; NONMEM;
D O I
10.1007/s10928-005-0049-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Leflunomide is a pyrimidine synthesis inhibitor used in the treatment of rheumatoid arthritis. Data from two clinical studies were used to establish a population pharmacokinetic (PPK) model for the active metabolite (M1) of leflunomide in patients with juvenile rheumatoid arthritis (JRA) and determine appropriate pediatric doses. Seventy-three subjects 3-17 years of age provided 674 M1 concentrations. The PPK model was derived from nonlinear mixed-effects modeling and qualified by cross-study evaluation and predictive check. A one-compartment model with first-order input described M1 PPK well. Body weight (WT) correlated weakly with oral clearance (CL/F = 0.020 center dot[WT/40](0.430)) and strongly with volume of distribution (V/F = 5.8 center dot[WT/40](0.769)). Steady-state concentrations (C-ss) of M1 in JRA were compared for a variety of leflunomide dose regimens using Monte-Carlo simulation. To achieve comparable C-ss values in pediatric patients with JRA to that in adult patients, doses of leflunomide should be adjusted modestly: 10 mg/d for 10-20 kg, 15 mg/d for 20-40 kg, and 20 mg/d for > 40 kg.
引用
收藏
页码:419 / 439
页数:21
相关论文
共 50 条
  • [31] Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis
    H. U. Schorlemmer
    R. Kurrle
    R. Schleyerbach
    R. R. Bartlett
    Inflammation Research, 1999, 48 (Suppl 2) : 113 - 114
  • [32] Leflunomide - A review of its use in active rheumatoid arthritis
    Prakash, A
    Jarvis, B
    DRUGS, 1999, 58 (06) : 1137 - 1164
  • [33] LONG-TERM SAFETY AND EFFECTIVENESS OF ADALIMUMAB IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE POLYARTICULAR OR POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS
    Horneff, G.
    Ruperto, N.
    Wallace, C.
    Bereswill, M.
    Cardoso, A.
    Kalabic, J.
    Kupper, H.
    Brunner, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 61 - 62
  • [34] Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis
    Schorlemmer, HU
    Kurrle, R
    Schleyerbach, R
    Bartlett, RR
    INFLAMMATION RESEARCH, 1999, 48 : S113 - S114
  • [35] Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis
    Goldenberg, MM
    CLINICAL THERAPEUTICS, 1999, 21 (11) : 1837 - 1852
  • [37] Leflunomide improves active rheumatoid arthritis equivalently to methotrexate
    Cronstein, BN
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (04) : 369 - 370
  • [38] The Efficacy and Safety of Leflunomide in Patients with Active Rheumatoid Arthritis
    Wiacek, Ryszard
    Kolossa, Katarzyna
    Jankowski, Tomasz
    Jeka, Slawomir
    Karmowski, Andrzej
    Karmowski, Mikolaj
    Gworys, Bohdan
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2012, 21 (03): : 337 - 342
  • [39] MITRAL AND AORTIC-INSUFFICIENCY IN POLYARTICULAR JUVENILE RHEUMATOID-ARTHRITIS
    OZER, S
    ALEHAN, D
    OZME, S
    BAKKALOGLU, A
    SOYLEMEZOGLU, O
    PEDIATRIC CARDIOLOGY, 1994, 15 (03) : 151 - 153
  • [40] Autoantibodies to hnRNP-A2/RA33 are associated with polyarticular course of juvenile rheumatoid arthritis (JRA)
    Hassfeld, W
    Vinie, O
    Steiner, G
    Skriner, K
    Smolen, JS
    Förre, Ö
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S343 - S343